The complement inhibitors market is experiencing a surge in growth as the role of the complement system in various diseases becomes increasingly understood. This report delves into the dynamic landscape of complement inhibitor development, highlighting key players, promising therapies, and the potential for groundbreaking treatments. Discover the latest clinical trial updates, including the latest research on Gefurulimab, ANX005, DNTH103, and more.
The RNA therapies market is experiencing explosive growth, driven by advancements in mRNA, siRNA, and antisense oligonucleotide therapies. Over 80 companies are actively developing 100+ RNA therapies across various stages, targeting diseases like cancer, infectious diseases, and genetic disorders. DelveInsight’s report, ‘RNA Therapies Competitive Landscape – 2024’, provides a comprehensive analysis of this dynamic market, highlighting key players, pipeline drugs, and future growth potential.
DelveInsight’s ‘Chronic Myelomonocytic Leukemia Pipeline Insight 2024’ report highlights the significant progress in the treatment of CMML, a rare blood cancer, with over 22 companies developing 25+ potential therapies. The report details key players, promising drugs like Tipifarnib and IO-202, and recent clinical trial updates.
